Physician profile
John A Spera
NPI 1306831813
$934.46
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $117 · 2024: $43.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $43.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $43.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $111.98 | 2019-2020 | |
| Janssen Biotech, INC. | $77.22 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $71.67 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $71.53 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.84 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $67.16 | 2019-2020 | |
| Array Biopharma INC | $49.60 | 2019 | |
| Ge Healthcare | $44.36 | 2019 | |
| Amgen INC. | $43.95 | 2019 | |
| Progenics Pharmaceuticals, INC. | $43.72 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $41.43 | 2019-2020 | |
| Exelixis INC. | $38.48 | 2019 | |
| Seagen INC. | $38.46 | 2019 | |
| Incyte Corporation | $29.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.75 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $24.31 | 2019 | |
| Puma Biotechnology, INC. | $23.04 | 2019 | |
| Eisai INC. | $22.73 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.60 | 2019 | |
| Clovis Oncology, INC. | $14.35 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.